[Skip to Navigation]
Comment & Response
January 2019

Regional Hyperthermia With Neoadjuvant Chemotherapy for Treatment of Soft Tissue Sarcoma—Reply

Author Affiliations
  • 1Institute of Medical Informatics, Biometry, and Epidemiology, LMU Munich, Munich, Germany
  • 2Department of Medicine III, University Hospital, LMU Munich, Munich, Germany
JAMA Oncol. 2019;5(1):114. doi:10.1001/jamaoncol.2018.5293

In Reply We thank Dr Sun et al and Dr Roussakow for their thoughtful comments on our recent article1 in JAMA Oncology.

Sun et al ask if overlapping median CIs contradict a significant difference in disease-free survival time. Slight overlap of CIs and reported significant difference is not a contradiction, as discussed by Austin and Hux.2 Furthermore, CIs for median overall survival (OS) do not exist because median OS cannot be estimated if the OS curves lay above the 50% survival margin.